Values First Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

Values First Advisors’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,498	Closed	-$125K	–	346
2023 Q1	$125K	Buy	+3,498	New	+$129K	0.08%	157

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Values First Advisors's XENE Position: Q2 2023 in Review

Values First Advisors sold out of Xenon Pharmaceuticals (XENE) in Q2 2023, closing a stake of 3,498 shares — an estimated $125K sold.

Values First Advisors first reported a position in XENE in Q1 2023 and held it in 1 quarter. The position peaked at $125K in Q1 2023. 175 funds tracked by Wall St. Rank hold XENE as of Q2 2023.

Values First Advisors reported no remaining Xenon Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Values First Advisors sold 3,498 Xenon Pharmaceuticals shares in Q2 2023, an estimated $125K.
Values First Advisors first reported a position in Xenon Pharmaceuticals in Q1 2023 and held it in 1 quarter.
Values First Advisors's Xenon Pharmaceuticals position peaked at $125K in Q1 2023.
175 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2023.

Based on Values First Advisors's 13F filing for Q2 2023, filed 2 Aug 2023.